-
Hyderabad: Hyderabad headquartered vaccine developer Bharat Biotech International Limited (BBIL) announced that its rotavirus oral vaccine Rotavac has been introduced by Nigeria to immunise its children from the life-threatening diarrhoeal disease. Nigeria currently accounts for 14% of all childhood rotavirus deaths globally, making it the country with the second-highest number of rotavirus deaths in the […]
-
Hyderabad: Bharat Biotech completed clinical development for Phase III trials and booster doses for India’s first intranasal Covid vaccine – BBV154. Two separate and simultaneous clinical trials were conducted to evaluate BBV154 as a primary dose (2-dose) schedule; and a heterologous booster dose for subjects who have previously received two doses of the two commonly […]
-
Hyderabad: Bharat Biotech International announced that its Covaxin has received emergency use approval in children aged between 6 and 12 years. It had conducted phase II/III, open-label, and multicenter studies to evaluate the safety, reactogenicity, and immunogenicity Covaxin in healthy children and adolescents in the 2-18 age group. The clinical trials conducted in the paediatric […]
-
New Delhi: The Subject Expert Committee (SEC) of the Drug Controller General of India (DCGI) has asked Bharat Biotech for additional data on its COVID-19 vaccine, Covaxin, for administering it to children aged between 2-12 years, sources said. This development comes after the Subject Expert Committee discussed recommendations for the restricted emergency of Covaxin in […]
-
Hyderabad: Biotechnology company Ocugen will commercialise Bharat Biotech’s Covaxin in Mexico. The two companies amended their present co-development, supply and commercialisation agreement on Bharat Biotech’s Covid-19 vaccine Covaxin to include Mexico. With this amendment, Ocugen now has commercialisation rights of Covaxin for all of North America. “We’re excited to commercialise Covaxin in Mexico, as authorities […]
-
Hyderabad: A day before Covid vaccine booster shots become available to all adult population, prices of Covaxin and Covidshield have been reduced to Rs 225 per dose for private hospitals. Suchitra Ella, Co-Founder and Joint Managing Director of Covaxin maker Bharat Biotech announced the decision on the micro-blogging platform Twitter. “We welcome the decision to […]
-
New Delhi: Hyderabad-based vaccine manufacturer Bharat Biotech on Friday announced the temporary slowing down of its Covid vaccine Covaxin’s production across its manufacturing facilities. “Bharat Biotech today announces the temporary slowing down of production of Covaxin across its manufacturing facilities, having completed its supply obligations to procurement agencies and foreseeing the decrease in demand,” it […]
-
Hyderabad: Padma Bhushan awardees Dr Krishna Ella and Suchitra Ella had moved to the US in late 1980s with just two suitcases and 14 years later when they decided to return to India, they had come back with a 40 feet container. “This container did not have our personal belongings but 70 per cent of […]
-
Hyderabad: The next pandemic, if it comes, will be on the animal side and food security issues, predicted Krishna Ella, Founder and Chairman of Bharat Biotech, that created the Covaxin. “I predict that, if the next pandemic comes, it will be on the animal side and food security issues. We do not want it to […]
-
Hyderabad: When Bharat Biotech was looking at developing vaccines after the Covid outbreak, the highest priority was ensuring the safety in adult vaccination, Dr Krishna Ella, managing director, Bharat Biotech International noted on Thursday. Speaking at a panel session on the first day of BioAsia titled ‘Two years into the pandemic – Challenges, successes and […]
-
Hyderabad: In response to the Covid pandemic, while the scientific achievements have been absolutely outstanding such as vaccines in less than a year and a lot of progress on diagnostics, self-test kits and antivirals, technology, and the genomic surveillance, which has allowed to track the evolution of the virus, but global coordination and harmony was […]
-
The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) had also recommended the internasal vaccine clinical trials during the last meeting.
-
New Delhi: Hyderabad-based Bharat Biotech on Wednesday claimed that its COVID vaccine Covaxin can neutralise both Delta and Omicron variants of coronavirus. In a statement, Bharat Biotech said, “Results from a study conducted at Emory University demonstrating that sera from subjects who received a booster dose of Covaxin (BBV152) six months after getting a primary […]
-
Hyderabad: Bharat Biotech, the maker of Covid-19 vaccine Covaxin, issued a fact check in response to certain media reports about the vaccine. Referring to a report dated December 29th 2021 by Moneycontrol, which stated, “No one can quite say how India’s indigenous Covid-19 vaccine company will meet the challenge of vaccinating close to 10 crore […]
-
Hyderabad: Vaccine maker Bharat Biotech on Wednesday clarified that Paracetamol or pain killers are not recommended for teenagers after being vaccinated with Covaxin. “We have received feedback that certain immunisation centres are recommending taking 3 paracetamol 500 mg tablets along with Covaxin for children. No paracetamol or painkillers are recommended after being vaccinated with Covaxin,” […]
-
New Delhi: The Subject Expert Committee (SEC) of the Drug Controller General of India (DCGI) is expected to meet on Tuesday afternoon to discuss Bharat Biotech’s application for clinical trials of its intranasal Covid vaccine as a booster or a third dose. The Hyderabad-based manufacturer has proposed the booster dose for those who have been […]
-
New Delhi: The Subject Expert Committee (SEC) of the Drug Controller General of India (DCGI) is expected to meet on Tuesday afternoon to discuss Bharat Biotech’s application for clinical trials of its intranasal Covid vaccine as a booster or a third dose. The Hyderabad-based manufacturer has proposed the booster dose for those who have been […]
-
New Delhi: Prime Minister Narendra Modi on Saturday announced that the COVID-19 vaccination for children aged 15-18 years will start from January 3. This comes after Bharat Biotech’s COVID-19 vaccine Covaxin has received approval from the Drugs Controller General of India (DCGI) for emergency use for kids aged between 12-18 years, said official sources. In […]
-
Hyderabad: Bharat Biotech has sought the approval of the Drug Controller General of India (DCGI) to conduct Phase 3 trials of its Covid-19 intranasal vaccine, sources said on Monday. The Hyderabad-based vaccine maker has submitted the application and awaiting approval for Phase 3 trials of intranasal vaccine (BBV154). “Intranasal vaccines have the potential to prevent […]
-
Hyderabad: Explaining its 28 days open vial policy, Hyderabad-based Bharat Biotech on Monday stated that healthcare workers do not have to worry about opening Covaxin’s vial and its wastage. This means that an open Covaxin vial can be used up to 28 days post opening and would not go waste if there are no people […]
